Get the Stockscreener App
3.57
6.08%
-0.21
Lixte Biotechnology Holdings Inc stock is traded at $3.57, with a volume of 89,604.
It is down -6.08% in the last 24 hours and down -12.35% over the past month.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
See More
Previous Close:
$3.78
Open:
$3.77
24h Volume:
89,604
Relative Volume:
0.92
Market Cap:
$31.16M
Revenue:
-
Net Income/Loss:
$-4.69M
P/E Ratio:
-1.5322
EPS:
-2.33
Net Cash Flow:
$-3.81M
1W Performance:
-8.97%
1M Performance:
-12.35%
6M Performance:
+25.44%
1Y Performance:
+47.92%
1-Day Range:
$3.50
$3.785
1-Week Range:
$3.50
$4.02
52-Week Range:
$0.64
$6.26
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Name
Lixte Biotechnology Holdings Inc
Sector
Industry
Phone
310 203 2902
Address
433 PLAZA REAL, BOCA RATON
Compare LIXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
3.58 | 32.90M | 0 | -4.69M | -3.81M | -2.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.16 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.22 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.06 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
802.27 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.79 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News
Will Lixte Biotechnology Holdings Inc. (8640) stock deliver compounding returns2026 world cup usa national team quarterfinals young talents transition play winner prediction breakdown - Улправда
What analysts say about Lixte Biotechnology Holdings Inc 8640 stockCandlestick Trading Patterns & High Return Stock Picks - earlytimes.in
What analysts say about SBCWW stockTechnical Breakout Signals & Free Wealth Planning Blueprints - earlytimes.in
Should You Add Aster DM Healthcare Limited Stock to Your Portfolio NowResistance Breakout Alerts & Minimal Capital Growth - earlytimes.in
Is Lixte Biotechnology Holdings Inc. stock trading at a premium valuationAnalyst Upgrades & Free High Yield Investment Strategies - bollywoodhelpline.com
Lixte Simplifies Capital Structure via Share Exchange Deal - TipRanks
Price Clustering Detected in Anupam Finserv Limited StockLong-Term Investment Plans & Low Risk High Yield - bollywoodhelpline.com
Will Lixte Biotechnology Holdings Inc. stock see insider buyingTake Profit Strategies & Low Entry Investment Portfolio - Bollywood Helpline
LIXTE expands clinical trial for ovarian cancer treatment By Investing.com - Investing.com Australia
Lixte Expands LB-100 Ovarian Cancer Trial Collaboration - TipRanks
Lixte expands LB-100 ovarian cancer trial collaboration - MSN
Key facts: Lixte Biotechnology secures $4.3M funding; expands cancer collaboration - TradingView — Track All Markets
LIXTE expands clinical trial for ovarian cancer treatment - Investing.com India
Lixte Biotechnology Holdings expands collaboration with University of Texas MD Anderson Cancer Center & GSK for LB-100 - marketscreener.com
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial - InvestorNews
Experimental ovarian cancer trial doubles the number of patients it will enroll - Stock Titan
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering - Investing.com Nigeria
Lixte Biotechnology Announces New Registered Direct Offering - TipRanks
Lixte Biotechnology Signs Multiple Material Agreements - TradingView — Track All Markets
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering By Investing.com - Investing.com South Africa
Lixte Biotechnology stock falls after $4.3 million direct offering - Investing.com
Lixte Biotechnology stock falls after $4.3 million direct offering By Investing.com - Investing.com Canada
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering - The Manila Times
Will Lixte Biotechnology Holdings Inc. stock keep outperforming rivalsJuly 2025 Setups & Advanced Technical Signal Analysis - Улправда
Whale Trades: Is Lixte Biotechnology Holdings Inc. Equity Warrant stock a contrarian buyMarket Growth Report & Entry and Exit Point Strategies - Улправда
Profit Recap: What sentiment indicators say about Lixte Biotechnology Holdings Inc stockJuly 2025 Big Picture & Weekly Consistent Profit Watchlists - moha.gov.vn
Momentum Shift: Is Lixte Biotechnology Holdings Inc. stock trading at a premium valuation2025 Analyst Calls & Fast Entry Momentum Trade Alerts - Улправда
Can Lixte Biotechnology Holdings Inc. Equity Warrant stock deliver consistent earnings growthPortfolio Gains Report & Fast Momentum Entry Tips - Улправда
What Wall Street predicts for Lixte Biotechnology Holdings Inc. Equity Warrant stock pricePortfolio Return Report & Daily Profit Maximizing Trade Tips - Улправда
Is Lixte Biotechnology Holdings Inc. Equity Warrant stock a contrarian buyTrade Risk Summary & Weekly Market Pulse Alerts - Улправда
Is Lixte Biotechnology Holdings Inc. stock a buy before product launchesInsider Buying & Expert Approved Trade Ideas - Улправда
Can Lixte Biotechnology Holdings Inc. stock continue upward trendPortfolio Update Summary & Real-Time Volume Triggers - ulpravda.ru
Will Lixte Biotechnology Holdings Inc. stock outperform tech sector in 2025Share Buyback & Stepwise Trade Execution Plans - Улправда
Why Lixte Biotechnology Holdings Inc. stock is a value investor pickJuly 2025 Trade Ideas & Scalable Portfolio Growth Ideas - DonanımHaber
Is Lixte Biotechnology Holdings Inc. Equity Warrant stock attractive for hedge funds2025 Technical Overview & Community Verified Watchlist Alerts - Улправда
Is Lixte Biotechnology Holdings Inc. (8640) stock nearing a technical breakoutQuarterly Profit Summary & Advanced Swing Trade Entry Alerts - DonanımHaber
What dividend safety rating applies to Lixte Biotechnology Holdings Inc. (8640) stockWeekly Trend Recap & AI Forecasted Entry/Exit Points - DonanımHaber
Will Lixte Biotechnology Holdings Inc. stock split again soon2025 Geopolitical Influence & Advanced Technical Signal Analysis - Улправда
Lixte Biotechnology shares dip after $4.3 million registered direct offering - MSN
Why Lixte Biotechnology Holdings Inc. (8640) stock is listed among top recommendationsMarket Activity Recap & Real-Time Volume Spike Alerts - Улправда
Lixte Biotechnology raises $4.3 million in registered direct offering By Investing.com - Investing.com India
Aug Sentiment: Is Lixte Biotechnology Holdings Inc. stock a buy before product launchesPortfolio Profit Report & Weekly High Potential Alerts - Улправда
Insider Trends: Will Lixte Biotechnology Holdings Inc. stock see insider buyingJuly 2025 Short Interest & Trade Opportunity Analysis Reports - Улправда
Lixte Biotechnology Launches $4.3 Million Registered Direct Offering - marketscreener.com
History Review: Will Lixte Biotechnology Holdings Inc. stock see insider buyingGap Up & Reliable Volume Spike Alerts - Улправда
Lixte Biotechnology prices $4.3M registered direct offering - MSN
Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):